Interview: André Choulika – Chairman and CEO, Cellectis, France
André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution;…
Expanscience is a family owned, independent French pharmaceutical and dermo-cosmetics laboratory, developing and manufacturing innovative osteoarthritis and skincare products. The company’s products, including two leading brands including Piascledine 300 and Mustela, are sold in more than 100 countries. With over 60 years of experience, Expanscience has built up a solid international reputation as an innovator and a specialist. The company prides itself in developing and marketing with active ingredients of natural origin for the French and international cosmetics industry. Thanks to a robust Corporate Social Responsibility program introduced over ten years ago, the company has made strong efforts in developing a sustainable and environmentally conscious business practice which has been recognized as exemplary by the AFAQ 26000 assessment in 2013. With a company motto: “Protecting Your Health Through Innovation,” Expanscience innovates to develop safe and effective solutions that do not harm people or the environment so that everyone can avoid osteoarthritis and skin problems.
Contact
10 avenue de l’Arche
92419 – Courbevoie
France
Tel : +33 (0)1 43 34 60 00
André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution;…
Serving as the leader of two companies – Platine, a CRO, and Indicia, a CMO – Stephane Legastelois, in his own words, challenges himself by wearing two different hats. Offering…
Laurence Comte-Arassus, president of Medtronic France, reveals how after the global acquisition of Covidien in January 2015, France is now their second largest subsidiary in the EMEA region; how Medtronic´s…
Nicolas Bardonnet, general manager of Promega France, reveals how France hosts both their European application laboratory and European training centre, offering a wide range of courses in molecular biology, cell…
The October 2015 merger between Houston, TX-based Cyberonics and Milan, Italy-based Sorin has led the creation of LivaNova, a medical device manufacturer active in the fields of cardiac surgery, neuromodulation…
Philippe Chêne, President of Winncare, reveals how he has led the company to be a force to be reckoned with as an advocate of preventative healthcare. An exemplary case of…
Christophe Lala, general manager of Western Europe at GE Healthcare, reveals how today the challenge is to ensure that all patients in France have access to the same medical pathway;…
Emmanuelle Ribot-Mariotte, general manager of Alfa Wassermann Pharma France, reveals how over the past year the company has been working hard on a new innovative treatment for hepatic encephalopathy, Rifaximin-alpha…
Finding success in the shadows of Big Pharma and large research facilities, CleveXel serves as a bridge in the industry, specializing on selecting promising molecules for investment, and developing them…
Prof. Thierry Philip, President of Institut Curie, is proud of the model that the institute is thriving for: excellent science and research in all forms, from the most basic to…
The recently appointed general manager of Galderma France, reveals the company’s ambitious objective for the next ten years: to increase sales from two to ten billion Euros (2.18 billion USD to…
Eric Goupil reveals how the global CMO market has expanded considerably over recent years, with a move towards a more strategic mind-set in the pharmaceutical industry. Unither´s business model is…
See our Cookie Privacy Policy Here
